Featured Courses

Examining the Clinical Potential of PARP Inhibitors in Prostate Cancer

AMA PRA Category 1 Credit(s)^TM

The advent of poly-(ADP ribose)-polymerase (PARP) inhibitors for a variety of malignancies has led to the evaluation of their use in patients with metastatic castrate resistant prostate cancer (mCRPC), and has the potential to shift treatment paradigms for these patients.

COVID-19 Infections and Hematologic Disturbances

AMA PRA Category 1 Credit(s)^TM

This education will provide physicians with the resources necessary to discuss treatment options with patients, payers and administrators to ensure that each stakeholder understands the importance of those options for the management of patients with hematologic malignancies and COVID-19.

Addressing Challenges in Diagnosis and Treatment of LG-UTUC

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

Join Dr. Seth Lerner, as he contrasts these 2 diseases, as well as important differences between low-grade and high-grade Upper tract urothelial carcinoma (UTUC).

Treating Patients with BRAF-Mutant or MSI-H mCRC | myCME

AMA PRA Category 1 Credit(s)^TM

0.75 AMA credits. Leading expert Dr. Dung Le discusses biomarker testing, treatment selection, and mitigating potential adverse events. Exp. 10/12/22.

Reduce Treatment Disparities in Multiple Myeloma | myCME

AMA PRA Category 1 Credit(s)^TM

1.00 CME/CE: Real-world strategies using data, guidelines, and decision-making recommendations to ensure the best care for patients with MM. Exp 12/23/22

Challenges in Patients With EGFR-Mutant NSCLC | myCME

AMA PRA Category 1 Credit(s)^TM

0.50 CME: Harvard’s Dr. Justin Gainor presents cases and questions learners about how they would proceed at different clinical decision points. Exp 12/30/22

Treatment Strategies for Myeloma | myCME

AMA PRA Category 1 Credit(s)^TM

This RME Hot Seat provides a virtual Q&A with a panel of multiple myeloma (MM) experts who field a range of questions on MM patient care, covering such topics as the use of minimal residual disease (MRD)–driven maintenance approaches, immunotherapy, the use of belantamab mafodotin, cytogenetic risk status, and the value of three-drug and four-drug regimens.

Episode 2: Pathophysiology of MDS and the MOA of Novel Agents

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, CNE Contact Hour(s)

This is the second of 3 episodes in this Oncology Prime Time series which will address diagnosis, risk stratification, and the mechanisms and clinical applications of new and emerging agents in MDS.

A 55-Year-Old Woman With Malignant Pheochromocytoma

AMA PRA Category 1 Credit(s)^TM

The goal of this activity is to provide clinicians with a brief review of pheochromocytoma and paraganglioma, its presentation, and the role of targeted therapeutics for metastatic disease.

Episode 3: Clinical Trial Data of New and Emerging Agents for MDS

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, CNE Contact Hour(s)

This is the third of 3 episodes in this Oncology Prime Time series which will address diagnosis, risk stratification, and the mechanisms and clinical applications of new and emerging agents in MDS.

Medical Moments Webinar Series: Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC | myCME

AMA PRA Category 1 Credit(s)^TM

This initiative examines the latest ADAURA trial data and the potential utility of adjuvant osimertinib in stage IB-IIIA EGFRm NSCLC.

PSMA PET Imaging in Detection of Prostate Cancer | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

1.50 CME/CE: 90-minute video on detecting prostate cancer with PSMA PET technology, including dosimetry, visualization, and patient tolerability. Exp 12/8/22